VVigilance Weekly공개 리포트 보기
← 이번 주 리포트
semaglutide우선순위 낮음근거 검토기타

LITERATURE DETAIL · PMID 42294355

Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.

Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.

저자
Franziska S Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M Burden
저널
The Lancet regional health. Europe
공개일
2026 Aug
연구 유형
기타
DOI
10.1016/j.lanepe.2026.101738

문헌 요약

The SUSTAIN-7 trial demonstrated greater HbA1c and bodyweight reductions with once-weekly semaglutide versus dulaglutide in type 2 diabetes, but strict eligibility criteria limit external validity. We evaluated the comparative real-world effectiveness and safety of these agents in UK primary care. Using the IQVIA Medical Research Data (IMRD) incorporating…

PV 검토 포인트

누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.

PubMed에서 원문 정보 보기